These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 23028063)
41. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Yan M; Rayoo M; Takano EA; ; Fox SB Breast Cancer Res Treat; 2011 Apr; 126(2):395-405. PubMed ID: 20490651 [TBL] [Abstract][Full Text] [Related]
42. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Zhang H; Pan Y; Zheng L; Choe C; Lindgren B; Jensen ED; Westendorf JJ; Cheng L; Huang H Cancer Res; 2011 May; 71(9):3257-67. PubMed ID: 21505104 [TBL] [Abstract][Full Text] [Related]
43. Combinatorial strategy of epigenetic and hormonal therapies: A novel promising approach for treating advanced prostate cancer. Motawi TK; Darwish HA; Diab I; Helmy MW; Noureldin MH Life Sci; 2018 Apr; 198():71-78. PubMed ID: 29455003 [TBL] [Abstract][Full Text] [Related]
44. Estrogen receptor β2 induces proliferation and invasiveness of triple negative breast cancer cells: association with regulation of PHD3 and HIF-1α. Bialesova L; Xu L; Gustafsson JÅ; Haldosen LA; Zhao C; Dahlman-Wright K Oncotarget; 2017 Sep; 8(44):76622-76633. PubMed ID: 29100336 [TBL] [Abstract][Full Text] [Related]
45. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Chu GC; Zhau HE; Wang R; Rogatko A; Feng X; Zayzafoon M; Liu Y; Farach-Carson MC; You S; Kim J; Freeman MR; Chung LW Endocr Relat Cancer; 2014 Apr; 21(2):311-26. PubMed ID: 24478054 [TBL] [Abstract][Full Text] [Related]
46. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Baniwal SK; Khalid O; Gabet Y; Shah RR; Purcell DJ; Mav D; Kohn-Gabet AE; Shi Y; Coetzee GA; Frenkel B Mol Cancer; 2010 Sep; 9():258. PubMed ID: 20863401 [TBL] [Abstract][Full Text] [Related]
47. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Shaaban AM; Green AR; Karthik S; Alizadeh Y; Hughes TA; Harkins L; Ellis IO; Robertson JF; Paish EC; Saunders PT; Groome NP; Speirs V Clin Cancer Res; 2008 Aug; 14(16):5228-35. PubMed ID: 18698041 [TBL] [Abstract][Full Text] [Related]
48. A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone. Kim B; Kim H; Jung S; Moon A; Noh DY; Lee ZH; Kim HJ; Kim HH J Bone Miner Res; 2020 Jan; 35(1):155-166. PubMed ID: 31505052 [TBL] [Abstract][Full Text] [Related]
49. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Odero-Marah VA; Wang R; Chu G; Zayzafoon M; Xu J; Shi C; Marshall FF; Zhau HE; Chung LW Cell Res; 2008 Aug; 18(8):858-70. PubMed ID: 18645583 [TBL] [Abstract][Full Text] [Related]
50. Expression of estrogen receptor beta wt isoform (ERbeta1) and ERbetaDelta5 splice variant mRNAs in sporadic breast cancer. Mandusić V; Nikolić-Vukosavljević D; Tanić N; Kanjer K; Neskovic-Konstantinović Z; Celeketić D; Dimitrijević B J Cancer Res Clin Oncol; 2007 Aug; 133(8):571-9. PubMed ID: 17457609 [TBL] [Abstract][Full Text] [Related]
51. The expression of estrogen receptors β2, 5 identifies and is associated with prognosis in non-small cell lung cancer. Liu Z; Liao Y; Tang H; Chen G Endocrine; 2013 Oct; 44(2):517-24. PubMed ID: 23475473 [TBL] [Abstract][Full Text] [Related]
52. Estrogen receptor β regulates AKT activity through up-regulation of INPP4B and inhibits migration of prostate cancer cell line PC-3. Chaurasiya S; Wu W; Strom AM; Warner M; Gustafsson JÅ Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26347-26355. PubMed ID: 33020300 [TBL] [Abstract][Full Text] [Related]
53. Effects of the Bone/Bone Marrow Microenvironments on Prostate Cancer Cells and CD59 Expression. Yan B; Li Y; Min S; Zhang P; Xu B; Wang Z; Zhang W; Chen J; Luo G; Liu C Biomed Res Int; 2020; 2020():2753414. PubMed ID: 32337233 [TBL] [Abstract][Full Text] [Related]
54. Cloning, expression and functional characterization on vitellogenesis of estrogen receptors in Scatophagus argus. Cui XF; Zhao Y; Chen HP; Deng SP; Jiang DN; Wu TL; Zhu CH; Li GL Gen Comp Endocrinol; 2017 May; 246():37-45. PubMed ID: 28322764 [TBL] [Abstract][Full Text] [Related]
55. Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade. Mickova A; Kharaishvili G; Kurfurstova D; Gachechiladze M; Kral M; Vacek O; Pokryvkova B; Mistrik M; Soucek K; Bouchal J Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799604 [TBL] [Abstract][Full Text] [Related]
56. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Campbell-Thompson M; Lynch IJ; Bhardwaj B Cancer Res; 2001 Jan; 61(2):632-40. PubMed ID: 11212261 [TBL] [Abstract][Full Text] [Related]
57. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study. Vinayagam R; Sibson DR; Holcombe C; Aachi V; Davies MP BMC Cancer; 2007 Jul; 7():131. PubMed ID: 17640362 [TBL] [Abstract][Full Text] [Related]
58. Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha. Collins F; MacPherson S; Brown P; Bombail V; Williams AR; Anderson RA; Jabbour HN; Saunders PT BMC Cancer; 2009 Sep; 9():330. PubMed ID: 19758455 [TBL] [Abstract][Full Text] [Related]
59. Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma. Chantzi NI; Tiniakos DG; Palaiologou M; Goutas N; Filippidis T; Vassilaros SD; Dhimolea E; Mitsiou DJ; Alexis MN J Cancer Res Clin Oncol; 2013 Sep; 139(9):1489-98. PubMed ID: 23817696 [TBL] [Abstract][Full Text] [Related]
60. GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer. Sawada Y; Kikugawa T; Iio H; Sakakibara I; Yoshida S; Ikedo A; Yanagihara Y; Saeki N; Győrffy B; Kishida T; Okubo Y; Nakamura Y; Miyagi Y; Saika T; Imai Y Int J Cancer; 2020 Mar; 146(5):1369-1382. PubMed ID: 31276604 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]